These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 9061066)

  • 21. Phase II clinical trial of 5-fluorouracil, trimetrexate, and leucovorin (NFL) in patients with advanced pancreatic cancer.
    Garcia AA; Leichman L; Baranda J; Pandit L; Lenz HJ; Leichman CG
    Int J Gastrointest Cancer; 2003; 34(2-3):79-86. PubMed ID: 15361639
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A weekly 24-h infusion of high-dose 5-fluorouracil (5-FU)+leucovorin and bi-weekly cisplatin (CDDP) was active and well tolerated in patients with non-colon digestive carcinomas.
    Caroli-Bosc FX; Van Laethem JL; Michel P; Gay F; Hendlisz A; Forget F; Bleiberg H
    Eur J Cancer; 2001 Oct; 37(15):1828-32. PubMed ID: 11576835
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cisplatin, etoposide, and weekly high-dose 5-fluorouracil and leucovorin infusion (PE-HDFL)--a very effective regimen with good patients' compliance for advanced gastric cancer.
    Cheng AL; Yeh KH; Lin JT; Hsu C; Liu MY
    Anticancer Res; 1998; 18(2B):1267-72. PubMed ID: 9615799
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intrahepatic chemotherapy with floxuridine, leucovorin and dexamethasone in continuous infusion and mitomycin-C bolus in unresectable hepatic metastases from colorectal cancer: a phase II study.
    Bertuccelli M; Falcone A; Campoccia S; Conti M; Brunetti I; Caramella D; Giulianotti PC; Mosca F; Bartolozzi C; Conte PF
    Tumori; 1999; 85(6):473-7. PubMed ID: 10774568
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase I study of weekly docetaxel, 24-hour infusion of high-dose fluorouracil/leucovorin and cisplatin in patients with advanced gastric cancer.
    Chen LT; Liu TW; Wu CW; Chung TR; Shiah HS; Jan CM; Liu JM; Whang-Peng J; Chang JY
    Oncology; 2002; 63(3):239-47. PubMed ID: 12381903
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil.
    Hsu CH; Cheng AL; Hsu C; Yang CH; Lu YS; Lin CC; Bu CF; Yeh KH
    Anticancer Res; 2002; 22(6B):3621-7. PubMed ID: 12552966
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neoadjuvant chemotherapy with cisplatin-vindesine-5-fluorouracil and folinic acid for locally advanced head and neck carcinoma.
    Bensmaine M el-A ; Guillot T; Bernal ET; Janot F; Sigal R; Domenge C; Wibault P; Armand JP; Cvitkovic E
    Am J Clin Oncol; 1996 Aug; 19(4):356-62. PubMed ID: 8677904
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study.
    de Gramont A; Bosset JF; Milan C; Rougier P; Bouché O; Etienne PL; Morvan F; Louvet C; Guillot T; François E; Bedenne L
    J Clin Oncol; 1997 Feb; 15(2):808-15. PubMed ID: 9053508
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase II evaluation of continuous-infusion 5-fluorouracil, leucovorin, mitomycin-C, and oral dipyridamole in advanced measurable pancreatic cancer: a North Central Cancer Treatment Group Trial.
    Burch PA; Ghosh C; Schroeder G; Allmer C; Woodhouse CL; Goldberg RM; Addo F; Bernath AM; Tschetter LK; Windschitl HE; Cobau CD
    Am J Clin Oncol; 2000 Oct; 23(5):534-7. PubMed ID: 11039519
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oxaliplatin in combination with infusional 5-fluorouracil and leucovorin every 2 weeks as first-line treatment in patients with advanced colorectal cancer: a phase II study.
    Kouroussis C; Souglakos J; Kakolyris S; Mavroudis D; Malamos N; Kalbakis K; Androulakis N; Agelaki A; Vardakis N; Samonis G; Georgoulias V
    Oncology; 2001; 61(1):36-41. PubMed ID: 11474246
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mitoxantrone, 5-fluorouracil and low-dose leucovorin in doxorubicin-resistant advanced breast cancer patients: a phase II study.
    Susnjar S; Vasović S; Nesković-Konstantinović Z; Stamatović L; Lukić V; Colaković S; Mitrovic L; Jelić S; Radulović S
    Tumori; 1999; 85(6):478-82. PubMed ID: 10774569
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epirubicin, cisplatin and continuous infusion 5-fluorouracil (ECF) in locally advanced or metastatic gastric cancer: a single institution experience.
    Aitini E; Rabbi C; Mambrini A; Cavazzini G; Pari F; Zamagni D; Cantore M; Pagani M; Sorio M; Lusenti A; Adami F; Smerieri F
    Tumori; 2001; 87(1):20-4. PubMed ID: 11669552
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomized trial of 5-fluorouracil, leucovorin and cisplatin in advanced pancreatic cancer.
    Huguier M; Barrier A; Valinas R; Flahault A; Adloff M; Pezet D; Jaeck D; Millat B;
    Hepatogastroenterology; 2001; 48(39):875-8. PubMed ID: 11462946
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cisplatin, cytarabine, caffeine, and continuously infused 5-fluorouracil (PACE) in the treatment of advanced pancreatic carcinoma: a phase II study.
    Ahmed S; Vaitkevicius VK; Zalupski MM; Du W; Arlauskas P; Gordon C; Kellogg C; Shields AF
    Am J Clin Oncol; 2000 Aug; 23(4):420-4. PubMed ID: 10955876
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of advanced pancreatic cancer with epirubicin, 5-fluorouracil and 1-leucovorin: a phase II study.
    Raderer M; Kornek GV; Hejna MH; Weinlaender G; Vorbeck F; Fiebiger WC; Scheithauer W
    Ann Oncol; 1997 Aug; 8(8):797-9. PubMed ID: 9332689
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Second-line chemotherapy with weekly oxaliplatin and high-dose 5-fluorouracil with folinic acid in metastatic colorectal carcinoma: a Hellenic Cooperative Oncology Group (HeCOG) phase II feasibility study.
    Janinis J; Papakostas P; Samelis G; Skarlos D; Papagianopoulos P; Fountzilas G
    Ann Oncol; 2000 Feb; 11(2):163-7. PubMed ID: 10761750
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase II trial of weekly paclitaxel, cisplatin plus infusional high dose 5-fluorouracil and leucovorin for metastatic urothelial carcinoma.
    Lin CC; Hsu CH; Huang CY; Cheng AL; Vogelzang NJ; Pu YS
    J Urol; 2007 Jan; 177(1):84-9; discussion 89. PubMed ID: 17162009
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cisplatin, 5-fluorouracil, and high-dose oral leucovorin for advanced head and neck cancer.
    Vokes EE; Schilsky RL; Weichselbaum RR; Guaspari A; Guarnieri CM; Whaling SM; Panje WR
    Cancer; 1989 Mar; 63(6 Suppl):1048-53. PubMed ID: 2783881
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phase II trial of 5-fluorouracil, leucovorin, and carboplatin in patients with unresectable biliary tree carcinoma.
    Sanz-Altamira PM; Ferrante K; Jenkins RL; Lewis WD; Huberman MS; Stuart KE
    Cancer; 1998 Jun; 82(12):2321-5. PubMed ID: 9635523
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Clinical evaluation of DLF, CLF and DFM regimens based on platinum compound plus 5-fluorouracil for treatment of advanced esophageal carcinoma].
    Jiang Y; Qiu XH; Yang YX; Zhang SQ; Chen ZM
    Ai Zheng; 2006 Aug; 25(8):1029-34. PubMed ID: 16965688
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.